权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Society for Basic Urologic Research 2021 Annual Meeting: Molecular Mechanisms of Urological Diseases and Treatment Resistance

泌尿基础研究学会2021年年会：泌尿系统疾病的分子机制及治疗耐药性

基本信息

批准号：
10384214
负责人：
Jindan Yu
金额：
$ 0.5万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-11-03 至 2022-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10384214
关键词：
Address Area Award Basic Science Benign Bioinformatics Biological Markers Biology CRISPR/Cas technology Cell Lineage Clinic Clinical Clinical Research Clustered Regularly Interspaced Short Palindromic Repeats Collaborations Development Disabled Persons Disadvantaged Disease Disease Resistance Emerging Technologies Endocrine Environment Environmental Risk Factor Epigenetic Process Fostering Funding Genetic Goals Immune response Immunotherapy Individual Infection Inflammation Intention Interdisciplinary Communication Knowledge Learning Malignant - descriptor Medical Medical Students Methodology Minority Modeling Molecular National Institute of Diabetes and Digestive and Kidney Diseases Oral Organoids Pathway interactions Persons Physicians Postdoctoral Fellow Prevention Process Regulation Request for Applications Request for Proposals Research Research Personnel Science Scientist Societies Technology Thinking Transgenic Organisms Translating Translational Research Travel Urologic Diseases Urology Woman career cost diagnostic strategy doctoral student environmental health disparity epigenetic regulation ethnic minority population health disparity interest meetings novel novel diagnostics novel therapeutics patient derived xenograft model posters pre-clinical racial and ethnic recruit stem cells symposium targeted treatment therapy resistant tool urologic

项目摘要

This application requests support for the Society for Basic Urologic Research (SBUR) 2021 Annual Meeting entitled, “Molecular Mechanisms of Urological Diseases and Treatment Resistance”, which will be held on November 4-7, 2021 at the JW Marriott Orlando Grande Lakes, Orlando, FL. This conference has been held annually since 1992 and provides a unique environment to learn about the most recent advances in basic, translational, and preclinical urologic research, in addition to providing a dynamic forum for discussing how these advances could be implemented for the prevention and treatment of urological diseases. Much has been learned over the last decade regarding the molecular determinants and key pathways that regulate normal and disease processes, and a wide variety of novel therapeutic and diagnostic strategies have emerged as a result. Thus, this year’s meeting will focus on a few areas that are emerging as the cutting-edge advances in urology, including: 1) Emerging Technologies and Models for Urological Research; 2) Endocrine and Genetic regulations in Urological Biology; 3) Epigenetic Regulations of Urological Development and Diseases; 4) Infection, Inflammation, and Immune Response in Urological Biology; 5) Biomarkers, Environmental Factors, and Health Disparities in Urological Diseases; 6) Urological Stem cells, Lineage Plasticity, and Treatment Resistance. The support from this application will be used to provide 24 Travel Awards and 4 Minority Scholar Awards to disadvantaged, poorly represented, trainees and junior to mid-career investigators to defray travel costs, with the intention of providing much-needed encouragement and promotion to a career in urologic research and of enhancing the diversity of conference attendees. In addition to highlighting recent advances and identifying key knowledge gaps, the primary goals of the conference are: 1) Discuss recent advances in studying the molecular mechanisms of urologic development and diseases using contemporary technologies, with emphasis on novel methodologies and tools, genetics, epigenetics, infection, inflammation and immune response, environmental factors and health disparity, and stem cells and lineage plasticity; 2) Identify critical knowledge gaps and stimulate approaches to address them; 3) Attract leading scientists from diverse fields in malignant and benign urology; 4) Promote interactions between basic, translational and clinical research scientists of diverse backgrounds and facilitate cross-disciplinary communication and collaboration; 5) Foster the active participation of women, minorities, the disabled, and early career investigators by providing them opportunities to present and discuss cutting-edge science and enhancing their integration into the field; and 6) Disseminate and facilitate novel discoveries in urologic diseases. An attendance of at least 250 is expected, and we will recruit a large variety of clinician, physician-scientist, and basic researcher attendees, with special emphasis on early-career investigators and groups typically underrepresented in urologic research. Finally, a robust plan is in place for publicizing the conference and the support, if awarded, by NCI and NIDDK.

本申请请求支持基础泌尿学研究学会（SBUR） 2021年年会